Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals Inc (NQ: RCKT )

11.74 -0.18 (-1.51%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rocket Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 Next >
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
From Rocket Pharmaceuticals, Inc.
Via Business Wire
What 5 Analyst Ratings Have To Say About Rocket Pharmaceuticals
Via Benzinga
Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
3 Small-Cap Stocks You Can’t Ignore Now
Finding promising small-cap stocks can be like a winning lottery ticket, providing years of steady and increasing gains to investors. 
Via InvestorPlace
Expert Ratings for Rocket Pharmaceuticals
Via Benzinga
Analyst Ratings for Rocket Pharmaceuticals
Via Benzinga
Rocket Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
5 Analysts Have This to Say About Rocket Pharmaceuticals
Via Benzinga
Rocket Pharmaceuticals Inc. (NASDAQ: RCKT) Sets New 52-Week High in Friday Session
Via Investor Brand Network
Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
What 6 Analyst Ratings Have To Say About Rocket Pharmaceuticals
Via Benzinga
The Latest Analyst Ratings for Rocket Pharmaceuticals
Via Benzinga
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Participate in the Bank of America Securities 2023 Healthcare Conference
From Rocket Pharmaceuticals, Inc
Via Business Wire
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
From Rocket Pharmaceuticals, Inc.
Via Business Wire
6 Questions With Rocket Pharma's CEO On World Health Day: How The Biotech Is 'Changing The Narrative'
Rocket Pharma (NASDAQ: RCKT) CEO Gaurav Shah is on a mission to "change the narrative" when it comes to rare diseases. 
Via Benzinga
Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharma COO On Observing Rare Disease Day, And Why It Deserves US Attention
Feb. 28 is Rare Disease Day. It's meant to observe the more than 400 million people globally — 50% of them children — that are affected by rare, pediatric life-threatening diseases such as leukemia,... 
Via Benzinga
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
Via Benzinga
3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways. 
Via MarketBeat
Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.